ArticleFrontiers in endocrinology2026
Multi-omics analysis explores the potential mechanisms of
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Methods: The chemical composition of DRS was profiled by widely targeted UPLC-MS/MS. Osteoporosis was induced in rats via bilateral ovariectomy, and bone status was assessed using serum biochemical analyses, micro-computed tomography (microCT) and hematoxylin-eosin (H&E) staining of femur tissue. Integrated multi-omics analyses were subsequently performed, comprising 16S rRNA sequencing of fecal microbiota, widely targeted serum metabolomics, and femoral transcriptomic sequencing. Results: DRS treatment significantly increased bone mineral density, improved trabecular bone microstructure, and effectively reversed abnormal bone turnover markers in OVX rats. Gut microbiota profiling indicated that DRS treatment modulated the gut microbiota, with significant increases in the relative abundance of Conclusion: DRS treatment protects against osteoporosis in OVX rats. This protection was associated with gut microbiota composition, serum metabolic profiles, and the expression balance between osteogenic and muscle-related genes in bone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.